Lianzhong Medical Completes Series D Financing to Advance Healthcare Big Data Initiatives

VCBeat (WeChat: vcbeat) has learned that Lianzhong Medical, a medical big data company, has recently signed a capital increase agreement with China Merchants Capital, the lead investor in its Series D financing. The hundreds of millions of yuan raised in this round will be used to further expand market share, continuously improve the company’s big data platform solutions, promote the development of its new medical DaaS (Data as a Service) business, and support forward-looking technological R&D.

LIANZHONG MEDICAL, established in 2010, is a platform-based medical technology company driven by big data, algorithms, and artificial intelligence, focusing on the application and governance of real-world, full-category medical examination data. As a national high-tech enterprise, the company holds more than 200 independent intellectual property rights, including invention patents such as “A Cloud Medical Image Storage System and Communication System” (some under substantive examination). It also possesses multiple qualifications, including CMMI-5 and Level 3 Classified Protection of Cybersecurity, and has passed cloud trustworthiness assessment and certification for its software systems in medical image information management and network communication, smart emergency cloud platform, remote consultation system, remote teaching system, and remote image diagnosis system. Furthermore, it is the contractor for the “National Medical Image Standard Library and Classification Library” project of the Chinese Society for Health Information and Big Data.

As one of the earliest vendors to develop regional medical cloud platforms in China, LIANZHONG MEDICAL’s “Global Imaging” is the first diagnostic-grade imaging cloud platform in China to obtain a Class II registration certificate for medical device software, and it is also one of the largest imaging cloud platforms globally. As of May 2021, the platform’s services had covered three provinces, including Guizhou, Liaoning, and Hainan, as well as more than 30 prefecture-level cities, with cumulative imaging data interactions exceeding 100 million instances and over 30 billion images. Meanwhile, keeping pace with international advanced technological trends, the platform has integrated emerging technologies such as 5G and blockchain into its applications, and collaborated with international research institutions like Duke University in the United States to promote the translation of related medical research achievements.

China Merchants Capital, the lead investor in this round, believes that the 21st century is an era of the digital economy. As a pioneer in China’s medical big data sector, LIANZHONG MEDICAL boasts strong technical capabilities and a spirit of innovation, with its team members possessing extensive experience in clinical medicine, big data, and artificial intelligence. At a time when many domestic medical AI companies had yet to identify viable business models, LIANZHONG MEDICAL had already pioneered the integration of the “Regional Imaging Cloud – Intelligent Medical Insurance Cost Control – Clinical Decision Support – Real-World Data Platform” pathway, providing highly valuable reference directions for the digital transformation of the entire healthcare industry. Mr. Wu Jiong, the founder, has profound insights into the healthcare industry and demonstrates clear foresight and uniqueness in judging the company’s strategic development direction. It is believed that under Mr. Wu Jiong’s leadership and with the support of both new and existing shareholders, LIANZHONG MEDICAL will stand out in the medical big data sector and become a significant force driving the rapid development of internet healthcare industries both nationally and globally.